ABBV/ENTA—There are about a million patients on dialysis between the 3 major markets (US EU JPN), so figure 100k addressable pts for whom Sovaldi-based regimens cannot be used.
Good to know!
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”